Pay in 4 interest-free payments of $5.85 Learn more
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7
In a phase 2 trial, once-monthly dosing produced significant weight loss at 52 weeks: 12.3% to 16.2% in patients with obesity without diabetes ( vs 2.5% with placebo), and 8.4% to -12.3% in those with obesity and type 2 diabetes ( vs 1.7% with placebo)
It has been reported to transport bile salts and bromosulfophtalein (BSP), steroid sulfates, thyroid hormones [triiodothyronine (T3), thyroxine (T4), and reverse T3], prostaglandin E2, fexofenadine, opioid peptides [e.g., deltorphin II and (-penicillamine)enkephalin], rocuronium, -methylquinine and -methylquinidine, ouabain, the endothelin receptor antagonist BQ-123, talinolol, and the thrombin inhibitor CRC-220 (Ianculescu et al
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial
The Future of Peptides: What's Coming
Evening application together is more convenient
US$ 27.82
US$ 22.73
US$ 21.14
US$ 22.81
US$ 29.65
US$ 25.13
US$ 24.43
US$ 21.42
US$ 24.98